Seeking Alpha

Mike Zaman's  Instablog

Mike Zaman
Send Message
View Mike Zaman's Instablogs on:
  • Atossa Genetics (ATOS) Pharmacogenetics Testing Momentum, General Moly (GMO) Insiders Confidence

    http://static.cdn-seekingalpha.com/uploads/2014/9/23/saupload_atos.jpg Atossa Genetics Inc. (NASDAQ:ATOS)

    Pharmacogenetics tests help doctors prescribe drugs and doses best suited for each person based on an analysis of their genetics.

    ATOS recently reported that its subsidiary, The National Reference Laboratory for Breast Health, Inc. (the NRLBH), has begun to offer pharmacogenetics testing. ATOS' NRLBH provided information about this new test, including:

    - Since first making the test available in late October 2014, the NRLBH has now processed more than 500 pharmacogenetics tests for U.S. patients with an average retail price of approximately $1,700 per patient. ATOS' NRLBH is also in the process of offering the test in select European markets

    - The NRLBH plans to utilize its third-party reimbursement firms, FedMed, MultiPlan and HealthSmart, to maximize the amount and speed of collections and help ensure that insurance companies that are members of these organizations pay for this test for their covered patients. Approximately 20% of Americans are covered by MultiPlan, and FedMed has more than 40 million members.

    ATOS expects that the pharmacogenetics testing revenue should add substantially to the company's bottom line and help finance its therapeutic development and device business in a non-dilutive manner.

    http://static.cdn-seekingalpha.com/uploads/2014/12/26/saupload_atosch21.png

    ATOS is focused on improving breast health through the development of laboratory services, medical devices and therapeutics.

    More about Atossa Genetics Inc. (ATOS) at www.atossagenetics.com.

    **

    http://static.cdn-seekingalpha.com/uploads/2014/12/26/saupload_gmo.jpg General Moly, Inc. (NYSEMKT:GMO)

    GMO said that it has signed definitive agreements with a group of accredited investors related to a private placement of units, consisting of senior convertible notes and warrants, for gross proceeds of $8.535 million. Of significance, one $5 million block was purchased by an investor with significant experience in the molybdenum sector, and GMO's executive management team and board of directors supported the Private Placement by investing over $2 million in aggregate.

    The Private Placement is expected to close on or around December 26, 2014 with proceeds from the offering to be used for maintenance of the Mt. Hope Project, the Liberty Project, and general corporate purposes. Read about the terms and conditions at generalmoly.com./news.php?releaseid=2001788

    According to GMO, the company remains focused on Mt. Hope financing, and is increasingly encouraged by the progress made, negotiations on investment agreement terms, sponsorship requirements, and indicative loan terms associated with a $700 to $750 million debt and equity package, are continuing to advance, and GMO has strong interest from multiple private Chinese industrial companies and a large Chinese bank in advancing the fully permitted, construction-ready project (these potential Chinese partners take a long term view, and believe as the company does, that the molybdenum price should strengthen by the time Mt Hope will start producing)

    http://static.cdn-seekingalpha.com/uploads/2014/12/26/saupload_gmoch.png

    GMO is a U.S.-based molybdenum mineral development, exploration and mining company. the company owns two world-class projects: an 80% interest in the fully permitted Mt. Hope Project and 100% of the Liberty Project, both in Nevada, U.S.A.

    More about General Moly, Inc. (GMO) at www.generalmoly.com.

    **

    http://static.cdn-seekingalpha.com/uploads/2014/12/23/saupload_crwe_logo.jpg Crown Equity Holdings Inc. (OTCPK:CRWE)

    The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.

    It has recently included Anaheim, a city in Orange County, California ( www.anaheim.crwe-pr.com ) to the CRWE Network.

    Situated between Los Angeles and San Diego, in the heart of Southern California, Anaheim has a diverse range of activities that make it one of the nation's most popular destinations. It is the second largest city in Orange County in terms of land area (after Irvine), and is known for its theme parks, sports teams and convention center.

    Anaheim boasts a diverse business community that has been established through effective planning, incentives, and business assistance. It has long been a center for industrial and technology companies and provides the right resources for manufacturers to remain competitive.

    The City of Anaheim had an estimated population in 2013 (U.S. Census Bureau) of 345,012, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally

    One of the primary goals of the CRWE Network is to offer business owners the power of consumer targeting advertisements on a local and national scale.

    The CRWE Network has reached the 1486th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.

    http://static.cdn-seekingalpha.com/uploads/2014/12/23/saupload_crwenov25.jpg

    http://static.cdn-seekingalpha.com/uploads/2014/12/18/saupload_crwe_network_business_direc.jpg The CRWE-PR Business Directory portal ( www.BusinessDirectory.crwe-pr.com ) is the company's business directory service that is available to all United States and Canada business in the public and private sector. It allows business owners and executives the ability to claim their business listings and provide more detailed information for their potential customers who visit the CRWE Network everyday.

    CRWE plans to have full national coverage of all U.S and Canada businesses in the future on its CRWE-PR Business Directory, which will be integrated to the CRWE Network.

    CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet

    More about Crown Equity Holdings Inc. (OTCPK:CRWE) at www.crownequityholdings.com

    **

    Disclaimer: This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer

    Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Dec 26 4:43 PM | Link | Comment!
  • LiveDeal (LIVE) Upcoming Moment Of Truth, OvaScience (OVAS) Rating Boosted

    http://static.cdn-seekingalpha.com/uploads/2014/8/13/saupload_live.jpg LiveDeal, Inc. (NASDAQ:LIVE)

    Keep a close eye on LIVE. The company said that it expects to release its year end 2014 financial results on December 29, 2014. LIVE's fiscal year ended on September 30, 2014.

    http://static.cdn-seekingalpha.com/uploads/2014/12/25/saupload_livech3.png

    LIVE provides marketing solutions that boost customer awareness and merchant visibility on the Internet. LIVE operates a deal engine, which is a service that connects merchants and consumers via an innovative platform that uses geo-location, enabling businesses to communicate real-time and instant offers to nearby consumers.

    More about LiveDeal, Inc. (LIVE) at www.livedeal.com.

    **

    http://static.cdn-seekingalpha.com/uploads/2014/12/25/saupload_ovas.jpg OvaScience, Inc. (NASDAQ:OVAS)

    OVAS was upgraded from Perform to Outperform by brokerage firm Oppenheimer.

    OVAS recently achieved its 2014 corporate goals to advance the AUGMENT SM, OvaPrime SM and OvaTure SM treatments for patients in need of new fertility treatment options

    The AUGMENT treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions outside of the United States. OVAS is developing the OvaPrime treatment, which could increase a woman's egg reserve, and the OvaTure treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections.

    http://static.cdn-seekingalpha.com/uploads/2014/12/25/saupload_ovasch.png

    OVAS is a global life sciences company dedicated to improving fertility for women around the world. The company is discovering, developing and commercializing new fertility treatments. Each OVAS treatment is based on the Company's proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC SM) cells - immature egg cells found inside the protective ovarian lining.

    More about OvaScience, Inc. (OVAS) at www.ovascience.com

    **

    http://static.cdn-seekingalpha.com/uploads/2014/12/23/saupload_crwe_logo.jpg Crown Equity Holdings Inc. (OTCPK:CRWE)

    The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.

    It has recently included Oakland, a major West Coast port city in California ( www.oakland.crwe-pr.com ) to the CRWE Network.

    The Port of Oakland is the busiest port for San Francisco Bay and all of Northern California. Oakland is the third largest city in the San Francisco Bay Area, the eighth-largest city in California, and the 45th-largest city in the U.S.

    Oakland's diverse population, hip arts scene, Mediterranean climate, world-class attractions, abundant parks and open spaces, vibrant waterfront and lakefront, historic architecture, palate-tempting restaurants, bustling nightlife, action-packed pro sports and varied recreation options make for an exciting destination.

    Oakland had an estimated population in 2013 (U.S. Census Bureau) of 406,253, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally

    One of the primary goals of the CRWE Network is to offer business owners the power of consumer targeting advertisements on a local and national scale.

    The CRWE Network has reached the 1486th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.

    http://static.cdn-seekingalpha.com/uploads/2014/12/23/saupload_crwenov25.jpg

    Together with its digital network of websites, CRWE provides and offers advertising branding, marketing solutions and services to boost customer awareness, as well as merchant visibility as a worldwide online multi-media publisher.

    More about Crown Equity Holdings Inc. (OTCPK:CRWE) at www.crownequityholdings.com

    **

    Disclaimer: This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer

    Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Dec 25 5:50 AM | Link | Comment!
  • GW Pharmaceuticals (GWPH) Sativex Cannabinoid Momentum, Novo Nordisk (NVO) FDA Oks Saxenda Injection For Obesity

    http://static.cdn-seekingalpha.com/uploads/2014/6/6/saupload_gwph.jpg GW Pharmaceuticals plc (NASDAQ:GWPH)

    Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body.

    Many people with multiple sclerosis experience spasticity, or muscle stiffness and spasms. It usually affects the muscles of the legs and arms, and may interfere with the ability to move those muscles freely.

    With normal muscle function, opposite muscles work in opposite directions, meaning that one muscle pulls while the other relaxes. Spasticity is a condition that occurs when opposite muscles both contract or relax at the same time, causing an increase in muscle tone.

    Spasticity may be as mild as the feeling of tightness of muscles or may be so severe as to produce painful, uncontrollable spasms of extremities, usually of the legs. Spasticity may also produce feelings of pain or tightness in and around joints, and can cause low back pain.

    In June 2010, GWPH reported the launch of Sativex(NYSE:R), its Oromucosal Spray for the treatment of spasticity due to Multiple Sclerosis. Sativex is the world's first prescription cannabis medicine and the UK was the first country in the world to grant a full regulatory authorization for the product.

    The medicine in Sativex is extracted from cannabis plants that have been selected and grown to produce a constant amount of active ingredients. Sativex is made under strictly controlled laboratory conditions and contains a balance of these active ingredients that have been shown to help improve the symptoms of multiple sclerosis spasticity.

    Currently, GWPH's Sativex is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States, and available for use in 15 countries. In-market sales volumes sold by GWPH's commercial partners for the 2014 fiscal year increased by 50% over 2013.

    GWPH's Sativex is also in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration (FDA) and in other markets around the world.

    http://static.cdn-seekingalpha.com/uploads/2014/12/24/saupload_gwph23.png

    GWPH is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GWPH commercialized the world's first plant-derived cannabinoid prescription drug, Sativex. GWPH is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex(R), which is in Phase 2/3 clinical development for the treatment of Dravet syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Lennox-Gastaut syndrome. GWPH has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia.

    More about GW Pharmaceuticals plc (GWPH) at www.gwpharm.com

    **

    http://static.cdn-seekingalpha.com/uploads/2014/12/24/saupload_nvo.jpgNovo Nordisk A/S (NYSE:NVO)

    The U.S. Food and Drug Administration (FDA) has approved Saxenda (liraglutide [rDNA origin] injection) as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.

    Saxenda (liraglutide), manufactured by NVO, is a glucagon-like peptide-1 (GLP-1) receptor agonist

    The drug is approved for use in adults with a body mass index (NYSE:BMI) of 30 or greater (obesity) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as hypertension, type 2 diabetes, or high cholesterol (dyslipidemia).

    BMI, which measures body fat based on an individual's weight and height, is used to define the obesity and overweight categories. According to the Centers for Disease Control and Prevention, more than one-third of adults in the United States are obese.

    The FDA approved liraglutide in 2010 as a treatment for type 2 diabetes, and NVO sells it under the name Victoza as a treatment for that condition. Saxenda contains a larger dose of liraglutide than Victoza does.

    http://static.cdn-seekingalpha.com/uploads/2014/12/24/saupload_nvoch.png

    NVO is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

    More about Novo Nordisk A/S (NVO) at www.novonordisk.com

    **

    http://static.cdn-seekingalpha.com/uploads/2014/12/23/saupload_crwe_logo.jpg Crown Equity Holdings Inc. (OTCPK:CRWE)

    The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.

    It has recently included the City of Fresno, CA ( www.fresno.crwe-pr.com ) to the CRWE Network.

    Fresno is the fifth largest city in the state of California. It is approximately 200 miles (320 km) north of Los Angeles, and 170 miles (270 km) south of the state capital, Sacramento.

    Centrally located, Fresno is the financial, industrial, trade, and commercial capital in the Central San Joaquin Valley.

    The City of Fresno had an estimated population in 2013 (U.S. Census Bureau) of 509,924, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally

    One of the primary goals of the CRWE Network is to offer business owners the power of consumer targeting advertisements on a local and national scale.

    The CRWE Network has reached the 1486th community website in the U.S., associated with 3456 ZIP Codes, and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.

    http://static.cdn-seekingalpha.com/uploads/2014/12/23/saupload_crwenov25.jpg

    CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet

    More about Crown Equity Holdings Inc. (OTCPK:CRWE) at www.crownequityholdings.com

    **

    Disclaimer: This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer

    Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Dec 24 1:16 AM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.